SIBN

SI-BONE, Inc. (SIBN) 2025 Annual Report Summary

Business Context and Reporting Period

This summary covers SI-BONE, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. SI-BONE is a medical device company specializing in minimally invasive procedural solutions for compromised bone, primarily focusing on sacroiliac joint dysfunction, thoracolumbar fixation, and pelvic trauma. The company markets its products through a direct sales force and third-party agents in the U.S. and internationally. As of year-end 2025, over 140,000 procedures had been performed using its products since 2009.

Key Financial Metrics

Cash Flow: Net cash used in operating activities improved significantly to $(0.7) million in 2025 compared to $(12.4) million in 2024. Net cash provided by investing activities was $4.2 million, and financing activities provided $3.4 million.

Material Changes vs. Prior Period

• Revenue Growth: Driven by a $32.7 million increase in U.S. revenue due to expanded product portfolio and a growing base of active physicians. International revenue increased by $1.1 million.
• Profitability Trend: While the company remains unprofitable, the net loss narrowed by $12.0 million year-over-year, primarily due to revenue growth outpacing expense increases.
• Expense Management: Sales and marketing expenses rose 6.1% due to higher commissions, while General and Administrative expenses increased 20.1% due to higher employee costs and legal/consulting fees.
• Product Mix: Gross margin expansion was attributed to favorable product mix changes, partially offset by higher royalties and inventory reserves.

Guidance, Outlook, Risks, and Contingencies

Outlook and Strategy: Management expects to continue incurring operating losses as it invests in R&D, commercial infrastructure, and new product development. The company aims to increase "surgical capacity" by deploying more instrument trays and expanding its sales force. Average revenue per territory sales manager increased to approximately $2.1 million in 2025.

Key Risks:

• Reimbursement Uncertainty: Significant risk exists regarding third-party payer coverage. While iFuse TORQ TNT received a New Technology Add-on Payment (NTAP) from CMS in October 2025, coverage for intra-articular procedures (CPT 27278) remains inconsistent, with some Medicare Administrative Contractors precluding coverage.
• Regulatory Investigation: In October 2024, the company received a Civil Investigative Demand (CID) from the U.S. Department of Justice regarding the Anti-Kickback Statute and False Claims Act, focusing on meals and consulting payments to healthcare professionals. The outcome is uncertain and could result in significant penalties.
• Supply Chain: The company relies on a limited number of third-party suppliers, including a single-source supplier (RMS Company) for key implants. Disruptions could materially impact operations.
• Competition: Intense competition from large medical device companies and new entrants may lead to pricing pressure and reduced market share.

Investor Verification Checklist

• Reimbursement Status: Verify the current status of CMS coverage determinations for CPT Code 27278 (intra-articular) and the sustainability of the NTAP for iFuse TORQ TNT.
• DOJ Investigation: Monitor updates regarding the Department of Justice investigation into marketing practices and potential settlement terms.
• Debt Covenants: Review the terms of the Fourth Amended Loan Agreement with First-Citizens Bank, specifically the financial covenants and the maturity date of September 1, 2029.
• Inventory Levels: Assess the $33.9 million inventory balance against sales velocity, given the company's history of inventory obsolescence charges.
• Patent Expirations: Note that U.S. patents on the original iFuse triangular shape are expected to expire by August 2028, potentially impacting competitive moats.